Personalized cell therapy aims to tame type 1 diabetes in early trial
NCT ID NCT06919354
First seen Jun 25, 2026 · Last updated Aug 11, 2026 · Updated 3 times
Summary
This early-stage study is testing a new treatment called GNTI-122 for adults who were recently diagnosed with type 1 diabetes. The therapy is made from a person's own blood cells and is designed to help rebalance the immune system. Sixteen participants will receive either a low or high dose of GNTI-122, with some also getting the drug rapamycin, and will be followed for 78 weeks to check safety and how well it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GNTI-122 (a cell therapy made from the patient's own blood cells, sometimes given with rapamycin)
- What this could lead to
- If successful, this could point toward a way to help people with newly diagnosed type 1 diabetes better control their blood sugar and reduce reliance on insulin.
- What could go wrong
- This is a very early, small study (16 people) focused mainly on safety. It may not show clear benefits, and the cell therapy might not work as hoped or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES (T1D) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
-
Columbia University
NOT_YET_RECRUITINGNew York, New York, 10032, United States
Contact Email: •••••@•••••
-
Duke University
RECRUITINGDurham, North Carolina, 27710, United States
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
-
Joslin Diabetes Center
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Email: •••••@•••••
-
University of California - San Diego
RECRUITINGSan Diego, California, 92093-0990, United States
Contact Email: •••••@•••••
-
University of California - San Francisco
RECRUITINGSan Francisco, California, 94158, United States
Contact Email: •••••@•••••
-
University of Florida - Gainesville
RECRUITINGGainesville, Florida, 32610, United States
-
University of Miami, Diabetes Research Institute
RECRUITINGMiami, Florida, 33136, United States
-
University of North Carolina at Chapel Hill
RECRUITINGChapel Hill, North Carolina, 27514, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Open-Source insulin systems match commercial ones without meal announcements?
- A glucose Monitor's second chance: can it tame type 1 diabetes in High-Risk teens?
- Could a smart pen take the guesswork out of insulin dosing?
- AI takes the wheel: could a smart algorithm optimize insulin pumps from home?
- Can a common diabetes pill make insulin therapy safer and more effective for type 1 diabetes?
- Could a metabolic modulator help people with type 1 diabetes use insulin better?